SCHEMBL17229237

SCHEMBL17229237

N#Cc1cn(CCCCCCCc2[nH]c(=O)[nH]c(=O)c2C#N)c(=O)[nH]c1=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.42
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
CYP2C9 P11712 3/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
CYP1A2 P05177 4/20 0.36
CYP2C19 P33261 3/20 0.36
MEN1 O00255 2/20 0.36
GAA P10253 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
TYMP P19971 1/20 0.35
DPYD Q12882 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP2D6 P10635 1/20 0.33
HPGD P15428 1/20 0.33
TK2 O00142 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15678760 0.84 KMT2A (0.39) KMT2ADRD2DRD3CYP2C9MAPT
SCHEMBL2353210 0.75 KMT2A (0.50) KMT2ADRD2DRD3CYP2C9MAPT
SCHEMBL3562882 0.71 KMT2A (0.49) KMT2ADRD2DRD3CYP2C9MAPT
SCHEMBL3571705 0.68 KMT2A (0.51) KMT2ADRD2DRD3CYP2C9MAPT
SCHEMBL13314181 0.67 KMT2A (0.53) KMT2ADRD2DRD3CYP2C9MAPT
SCHEMBL13401727 0.65 KMT2A (0.38) KMT2ADRD2DRD3CYP2C9MAPT
SCHEMBL1690845 0.65 TYMP (0.44) KMT2ACYP2C9MAPTSMN1; SMN2CYP1A2
SCHEMBL11708542 0.64 KMT2A (0.68) KMT2ASMN1; SMN2TDP1CYP1A2MEN1
SCHEMBL2248519 0.64 KMT2A (0.52) KMT2ACYP2C9SMN1; SMN2TDP1CYP1A2
SCHEMBL3559425 0.63 KMT2A (0.55) KMT2ADRD2DRD3CYP2C9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER LIG1, LIG4, LIG3 KMT2A 1608/4885DRD2 4178/4885DRD3 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.